In the STEP 1 extension study, participants who stopped semaglutide after treatment regained a substantial portion of the weight they had lost during the following year, and cardiometabolic improvements moved back toward baseline
At this point, the medication begins regulating blood sugar levels. After at least four weeks on a 0.5 mg dose, your provider may increase your weekly dose up to the maximum recommended dosage of 1.0 mg if you need additional glycemic control
He said I seemed like a great candidate, she said
Transitioning between GLP-1-based medications is generally possible under medical supervision
Mol Metab 18:314 Holst JJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK (2017) Glucagon and amino acids are linked in a mutual feedback cycle: the liver--cell axis
NAD+ supplements (typically NR or NMN) raise cellular coenzyme levels, whilst retatrutide is an unlicensed investigational triple receptor agonist (GLP-1, GIP, glucagon) not yet approved by the MHRA or EMA for use in the UK